Zim Laboratories Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Zim Laboratories’ record is clean on audit opinions and regulatory discipline, but the numbers tell a harder story: operating cash flow has consistently outstripped profit, yet returns on capital have halved in three years while ₹95.53 crore sits in unfinished assets, and a critical EU GMP audit has halted a flagship product line with no restart date.

Key findings

  1. Operating cash beats profit, but capital is stuck in ageing projects and returns have halved Major - Consolidated cash from operations exceeded profit after tax in every year from FY21 through FY26, with FY26 CFO of ₹49.53 crore against PAT of just ₹5.84 crore. That cash is being absorbed by capital work in progress of ₹95.53 crore, 61% of net fixed assets, while consolidated ROCE fell from 15.59% in FY23 to 5.10% in FY26. No dividend was paid in FY20, FY21, FY25, or FY26.
  2. Export shift collides with an EU GMP audit that has stopped a key product Major - Exports rose from 63% of operating income in FY20 to 83% in FY25, and licensing income was ₹9.8 crore that year. Management stated in Q4 FY26 that licensing fees were “substantially lower” because milestones are “linked to having the EU GMP,” and that Sildenafil OTF commercial supplies “have stopped” pending reinstatement. Combined NIP and OTF revenue fell from ₹62 crore to ₹48 crore year-on-year in FY26.
  3. Disputed tax demands and a GST notice sit without provisions Minor - As at 31 March 2026, the standalone financial statements disclose contingent liabilities for disputed income tax (₹395.95 lakhs), GST (₹28.73 lakhs), and import duty (₹585.07 lakhs), none of which have been provided for. A GST demand notice dated 30 December 2025 for FY22 totalling ₹2.19 crore was also received, and the company stated it would file an appeal. The company has repeated in every annual report since FY20 that the potential past provident fund liability from the Supreme Court judgement of 28 February 2019 cannot be reasonably ascertained and remains unprovided.
  4. Promoter pay is decoupled from profits with shareholder approval Minor - The board sought and obtained shareholder approval at the AGM on 29 June 2026 for payment of remuneration to the Managing Director and Whole-Time Director in the event of absence or inadequacy of profits for three years starting FY27. A postal ballot notice dated 10 July 2026 proposes revising the Managing Director’s fixed pay to up to ₹3.00 crore and the Whole-Time Director’s to up to ₹2.50 crore, removing the lower limit. Standalone PAT fell from ₹17.25 crore in FY24 to ₹5.84 crore in FY26.
  5. An offshore group structure holds three long-non-operational subsidiaries and one liquidated entity Minor - As of FY26, the group comprised seven entities across India, UAE, Latvia, and Australia. Three subsidiaries had yet to commence operations: ZIM Thinorals (incorporated May 2021), SIA ZIM Laboratories Latvia (incorporated September 2019), and ZIMTAS PTY Australia (acquired March 2024). ZIM Laboratories Middle East DMCC, incorporated in September 2023, was liquidated effective 23 February 2026 without ever commencing business.
  6. The auditor change followed the statutory term limit with near-unanimous approval Clean - Walker Chandiok & Co LLP completed its maximum two consecutive five-year terms and Deloitte Haskins & Sells LLP was appointed for a first term of five years from the AGM held on 27 June 2025, with 99.9998% of votes in favour. No regulatory actions against either auditor were disclosed.

What to watch

Bottom line: This is a disclosed and consistently audited record with genuine cash generation. The risk sits in two places: the EU GMP audit, which has already stopped a product line and depressed licensing income, and the ₹95.53 crore of capital locked in unfinished assets while returns on that capital have fallen to 5%. Watch the GMP reinstatement and the CWIP commissioning dates, until those land, the cash flow story remains incomplete.